CA2956788A1 - Analogues de fumarate et leurs utilisations dans le traitement d'une maladie auto-immune ou d'une maladie inflammatoire - Google Patents

Analogues de fumarate et leurs utilisations dans le traitement d'une maladie auto-immune ou d'une maladie inflammatoire Download PDF

Info

Publication number
CA2956788A1
CA2956788A1 CA2956788A CA2956788A CA2956788A1 CA 2956788 A1 CA2956788 A1 CA 2956788A1 CA 2956788 A CA2956788 A CA 2956788A CA 2956788 A CA2956788 A CA 2956788A CA 2956788 A1 CA2956788 A1 CA 2956788A1
Authority
CA
Canada
Prior art keywords
substituted
alkyl
certain embodiments
compound
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2956788A
Other languages
English (en)
Inventor
Matthew Duncton
Somasekhar Bhamidipati
Jiaxin Yu
Ihab Darwish
Rajinder Singh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rigel Pharmaceuticals Inc
Original Assignee
Rigel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigel Pharmaceuticals Inc filed Critical Rigel Pharmaceuticals Inc
Publication of CA2956788A1 publication Critical patent/CA2956788A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Selon certains aspects, cette divulgation concerne des composés de formule (A) qui trouvent une utilisation dans le traitement de diverses maladies et affections auto-immunes et inflammatoires. Selon d'autres aspects, des compositions pharmaceutiques contenant lesdits composés, des méthodes d'utilisation de ces composés dans le traitement de diverses maladies et affections, des procédés pour les préparer ainsi que pour préparer des intermédiaires utiles dans lesdits procédés sont en outre décrits. Formule (A).
CA2956788A 2014-08-04 2015-07-31 Analogues de fumarate et leurs utilisations dans le traitement d'une maladie auto-immune ou d'une maladie inflammatoire Abandoned CA2956788A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462033023P 2014-08-04 2014-08-04
US62/033,023 2014-08-04
PCT/US2015/043279 WO2016022434A1 (fr) 2014-08-04 2015-07-31 Analogues de fumarate et leurs utilisations dans le traitement d'une maladie auto-immune ou d'une maladie inflammatoire

Publications (1)

Publication Number Publication Date
CA2956788A1 true CA2956788A1 (fr) 2016-02-11

Family

ID=54062798

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2956788A Abandoned CA2956788A1 (fr) 2014-08-04 2015-07-31 Analogues de fumarate et leurs utilisations dans le traitement d'une maladie auto-immune ou d'une maladie inflammatoire

Country Status (9)

Country Link
US (4) US9475781B2 (fr)
EP (1) EP3177599B1 (fr)
JP (2) JP6735729B2 (fr)
CN (1) CN106573901B (fr)
CA (1) CA2956788A1 (fr)
DK (1) DK3177599T3 (fr)
ES (1) ES2775433T3 (fr)
PT (1) PT3177599T (fr)
WO (1) WO2016022434A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3177599T3 (da) * 2014-08-04 2020-03-09 Rigel Pharmaceuticals Inc Fumarat-analoger og anvendelser heraf ved behandling af en autoimmun sygdom eller en inflammatorisk sygdom
CA3013080A1 (fr) 2016-02-03 2017-08-10 Rigel Pharmaceuticals, Inc. Composes activant nrf2 et leurs utilisations
PL3411368T3 (pl) 2016-02-03 2020-11-16 Rigel Pharmaceuticals, Inc. Związki aktywujące nrf2 i ich zastosowania
EP3793991A4 (fr) * 2018-05-16 2022-01-12 Rigel Pharmaceuticals, Inc. Promédicaments de composés activateurs de nrf2 et leurs utilisations
EP4096365A4 (fr) 2020-01-20 2023-07-12 Koito Manufacturing Co., Ltd. Circuit d'éclairage et voyant lumineux de direction de véhicule

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501370D0 (en) * 1995-01-24 1995-03-15 Exxon Chemical Patents Inc Additive concentrate
JPH08259547A (ja) 1995-03-20 1996-10-08 Nippon Bayeragrochem Kk 除草性１−アルケニルテトラゾリノン類
DK2334378T3 (da) 2008-08-19 2014-07-07 Xenoport Inc Prodrugs af methylhydrogenfumarat, farmaceutiske sammensætninger deraf og fremgangsmåder til anvendelse
WO2011140190A1 (fr) * 2010-05-05 2011-11-10 Infinity Pharmaceuticals Tétrazolones utilisés en tant qu'inhibiteurs d'acide gras synthase (fasn)
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
DK3177599T3 (da) * 2014-08-04 2020-03-09 Rigel Pharmaceuticals Inc Fumarat-analoger og anvendelser heraf ved behandling af en autoimmun sygdom eller en inflammatorisk sygdom
CA2974900A1 (fr) * 2015-01-26 2016-08-04 Rigel Pharmaceuticals, Inc. Tretrazolones utilisees comme bioisosteres d'acide carboxylique

Also Published As

Publication number Publication date
US9801866B2 (en) 2017-10-31
JP6965390B2 (ja) 2021-11-10
US20200155531A1 (en) 2020-05-21
US20160039773A1 (en) 2016-02-11
ES2775433T3 (es) 2020-07-27
US20170065569A1 (en) 2017-03-09
US20180071271A1 (en) 2018-03-15
US10493066B2 (en) 2019-12-03
JP6735729B2 (ja) 2020-08-05
JP2017523978A (ja) 2017-08-24
JP2020114844A (ja) 2020-07-30
US9475781B2 (en) 2016-10-25
EP3177599A1 (fr) 2017-06-14
CN106573901A (zh) 2017-04-19
US11129819B2 (en) 2021-09-28
CN106573901B (zh) 2021-03-02
EP3177599B1 (fr) 2019-12-04
DK3177599T3 (da) 2020-03-09
PT3177599T (pt) 2020-03-05
WO2016022434A1 (fr) 2016-02-11

Similar Documents

Publication Publication Date Title
US11129819B2 (en) Fumarate analogs and uses thereof
US11279686B2 (en) Nrf2 activating compounds and uses thereof
US10941135B2 (en) Nrf2 activating compounds and uses thereof
US10889562B2 (en) Prodrugs of Nrf2 activating compounds and uses thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200721

FZDE Discontinued

Effective date: 20240402